Structure Therapeutics CEO Raymond Stevens discusses obesity drugs and the company's expansion plans with Katie Greifeld at ...

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...

CEO Dave Ricks said Monday that the company's GLP-1 weight-loss pill orforglipron could receive FDA approval as soon as early ...

As Lyndra Therapeutics works to advance long-acting oral drugs for a range of diseases, the Massachusetts-based biotech is ...

The U.S. on Wednesday banned the use of a synthetic food dye that gives some candies, cakes and certain oral medications a ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

It is also developing the drug as a first-line alternative to complement-targeting antibodies in the APPOINT-PNH trial due to read out in January. Image Phil Taylor ...

Lyndra Therapeutics and Thermo Fisher Scientific have entered a strategic partnership for Lyndra's long-acting oral therapies ...

Dr. Scott Manthei of the Nevada Ear and Sinus Institute has been advising patients against taking drugs like Sudafed for ...

Lupkynis is in the well-established calcineurin inhibitor class of immunosuppressants, which includes oral drugs like cyclosporine and tacrolimus that have both been used off-label to treat LN.

An oral form of Ozempic – Rybelsus ... “A couple of years ago there was an article published in Nature about an exercise pill that was based on a molecule called lactate phenylalanine ...